Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414157 | 0.88 | ALDH1A1 (0.53) | GAAMAPTALDH1A1CA1CA2 | |
| SCHEMBL29746207 | 0.88 | ALDH1A1 (0.53) | GAAMAPTALDH1A1CA1CA2 | |
| SCHEMBL29778868 | 0.86 | CA1 (0.47) | GAAMAPTALDH1A1CA1CA2 | |
| SCHEMBL2429565 | 0.86 | POLB (0.41) | GAAMAPTALDH1A1TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL8947519 | 0.86 | ALDH1A1 (0.52) | GAAMAPTALDH1A1CA1CA2 | |
| SCHEMBL21603365 | 0.86 | CA1 (0.47) | GAAMAPTALDH1A1CA1CA2 | |
| SCHEMBL5176788 | 0.84 | CA1 (0.46) | GAAMAPTALDH1A1CA1CA2 | |
| SCHEMBL29778899 | 0.84 | CA1 (0.46) | GAAMAPTALDH1A1CA1CA2 | |
| SCHEMBL7713740 | 0.84 | CA1 (0.46) | GAAMAPTALDH1A1CA1CA2 | |
| SCHEMBL1274565 | 0.80 | GAA (0.46) | GAAMAPTCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005100434-A1 | HALOGEN CONTAINING EPOXY COMPOSITIONS AND THEIR PREPARATION | UNIVERSITY OF NORTH TEXAS (US) | 2005-10-27 | — | — | WO | claimed |
| US-20050228080-A1 | Halogen containing epoxy compositions and their preparation | UNIVERSITY OF NORTH TEXAS (US) | 2005-10-13 | — | — | US | claimed |
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12610730-B2 | Metal complex and light emitting device | CITY UNIVERSITY OF HONG KONG (HK) | 2026-04-21 | — | — | US | disclosed |
| EP-4559525-A2 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | Morphic Therapeutic, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4558493-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | Iambic Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119894880-A | Quinazoline compounds and methods of use | 依安彼克医疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4045039-B1 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | MORPHIC THERAPEUTIC INC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119192137-A | Inhibition of human integrin alpha4β7 | 莫菲克医疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240174632-A1 | INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) | MORPHIC THERAPEUTIC, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240092761-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-4379819-A | OIL SOLUBLE MONOAZO DYE | CIBA-GEIGY AG (CH) | 1983-04-12 | — | — | US | disclosed |
| WO-1983000332-A1 | N-PHENYLPYRAZOLE DERIVATIVES USEFUL AS HERBICIDES | MAY & BAKER LTD (GB) | 1983-02-03 | — | — | WO | disclosed |
| EP-0039312-A1 | Colour photopgraphic material for the silver-dye bleaching process, process for the production of this material and its use in the production of photographic images | CIBA-GEIGY AG (CH) | 1981-11-04 | — | — | EP | disclosed |
| EP-0036081-A1 | Azo dyestuffs as well as their preparation and their use in dyeing synthetic fibres | BAYER AG (DE) | 1981-09-23 | — | — | EP | disclosed |
| US-4237048-A | COLORFASTNESS; FOR DYEING NATURAL AND SYNTHETIC FIBERS | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-02 | — | — | US | disclosed |
| US-4105655-A | PHENYL-AZO-ANILINO DYESTUFF | BAYER AKTIENGESELLSCHAFT (DE) | 1978-08-08 | — | — | US | disclosed |
| US-4083844-A | Phenylazo orthocyano phenylazo or orthocyano phenylazo phenylazo containing dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1978-04-11 | — | — | US | disclosed |
| US-3978040-A | Process for the preparation of cyanoazo compounds by reacting halogenoazo compounds with CuCN in an aqueous media in the presence of a nitrogen base | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-31 | — | — | US | disclosed |
| US-3962209-A | PROCESS FOR PREPARING AZO DYESTUFFS WITH ORTHO-AZO CYANO GROUPS BY CYANO EXCHANGE OF METAL CYANIDES AND HALO DYESTUFFS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | SLC10A1, NR3C2, CYP2C8 | GAA 238/4885MAPT 3402/4885ALDH1A1 230/4885 |
| US-20240092761-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | CCNI, CDK3, CDK1 | GAA 913/4885MAPT 3577/4885ALDH1A1 568/4885 |
| US-12610730-B2 | Metal complex and light emitting device | OPRD1, OCIAD2, ORC3 | GAA 4797/4885MAPT 1899/4885ALDH1A1 4413/4885 |
| US-20240174632-A1 | INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) | ITGB7, ITGB4, ITGA4 | GAA 792/4885MAPT 3333/4885ALDH1A1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.